CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.

Naproxen is a small molecule drug that inhibits COX enzymes, with active indications including pain, gout, inflammation, ankylosing spondylitis, and juvenile arthritis.

Famotidine is a medicine that helps people with stomach problems like gastritis and peptic ulcers.

Flare Therapeutics Unveils Design for FX-909's Early-Stage Trial with Dose Increasing and Widening Approach at ASCO's 2024 Urologic Cancer Conference.

Amoxicillin Trihydrate is a cell wall inhibitor drug used as an antibiotic to treat bacterial infections like bronchitis, pneumonia, urinary tract infections, and strep throat.

LAVA Therapeutics reveals a partnership with Merck & Co., US, to assess the potential of combining LAVA-1207 with the treatment, KEYTRUDA®.

Ibuprofen, a COX-inhibiting drug approved by Johnson & Johnson in 1978, is primarily used to manage rheumatoid arthritis, arthritis, fever, and pain.

Metoprolol Tartrate is a medication that blocks β-adrenoceptors, and it was approved in 1978 by AstraZeneca PLC.

Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.

Atorvastatin is a medication that inhibits the HMG-CoA reductase enzyme. Hanmi Pharmaceutical Co., Ltd approved it in January 2008.

Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Trazodone, a selective inhibitor of serotonin reuptake transporter 5, has been a key treatment for depression since its approval in Dec 1981 by Angelini Pharma.